CLAIM DESK / COMPARISON MATRIX
Compare the Evidence, Not the Hype
KPV, semaglutide, CJC-1295, and NAD+ aligned by what they are, what was measured, and how far each conclusion can travel.
The short version
These four records do not form a treatment ladder. They concern different molecules, pathways, research questions, and evidence levels. KPV is a tripeptide studied mainly in cells and animals for inflammatory signaling [1][2][3][4]. Semaglutide is a modified peptide medicine with large randomized human outcome trials [9][10][11]. CJC-1295 is a GHRH analogue with small human pharmacology studies showing sustained GH/IGF-1 stimulation [15][16][17]. NAD+ is a coenzyme, not a peptide, and oral human research mainly concerns its precursors NMN and NR [18][19][20][22].
The most reliable comparison therefore asks three questions: What model generated the result? What endpoint changed? What source defines the boundary? A molecular mechanism may be well established even when a health benefit is not. A blood marker may move without changing a clinical outcome. A large trial may establish one outcome only in a defined population. The matrix below keeps those distinctions in view and supplies no personal-use recommendation.
The claim-checking matrix
| Dimension | KPV | Semaglutide | CJC-1295 | NAD+ |
|---|---|---|---|---|
| What it is | Melanocortin-derived tripeptide | Modified GLP-1 peptide agonist | Modified GHRH peptide analogue | Dinucleotide coenzyme; not a peptide |
| Main pathway | PepT1 uptake; inflammatory signaling | GLP-1 receptor signaling | GHRH receptor to GH/IGF-1 axis | Redox metabolism; sirtuins, PARPs, CD38 |
| Main cited models | Cells, mice, rabbits, reviews [1][2][3][4][6] | Large randomized human trials and safety review [9][10][11][12] | Small studies in healthy adults and analytical chemistry [14][15][16][17] | Human precursor trials and reviews [18][19][20][21][22] |
| Typical endpoint | Cytokines, colitis severity, wound closure | Body-weight change, kidney and cardiovascular events | GH, IGF-1, serum protein signals | Blood NAD+, insulin sensitivity, walking or quality-of-life measures |
| Evidence maturity | Preclinical | Mature clinical | Early human pharmacology | Mechanistically mature; clinical translation limited |
| Central caution | No established human efficacy or safety | Known tolerability issues and population-specific interpretation | Biological activity is not proven therapeutic benefit | Biomarker change is not longevity evidence |
Mechanism: four different questions
KPV asks whether a small alpha-MSH-derived fragment can modulate inflammatory pathways without pigmentary action. Its PepT1 transport and suppression of NF-kB and MAP-kinase signaling are supported in intestinal cells and mouse models [3][5]. Semaglutide asks what follows from long-acting GLP-1 receptor activation across metabolic and appetite circuits; outcome trials then test whether the mechanism translates to clinical events [9][10][11].
CJC-1295 asks whether albumin-linked GHRH signaling can sustain stimulation of the GH/IGF-1 axis while retaining natural pulses. Small studies answer that pharmacology question affirmatively [16][17]. NAD+ research asks whether replenishing a central cellular coenzyme through precursors changes metabolism or function. The basic coenzyme biology is strong [21], while human translation remains mixed [18]. The mechanisms are not comparable on a single scale; each frames a different hypothesis.
Evidence maturity: count the steps
Evidence maturity is not captured by whether a result is “positive.” KPV has several coherent preclinical findings, including targeted-delivery experiments [1][2]. The missing step is controlled human testing. CJC-1295 crosses that boundary only narrowly: small human studies demonstrate hormonal and proteomic changes [15][16][17], but they do not establish broad clinical benefits or long-term safety.
NAD+ precursor trials include randomized human designs and useful endpoints [19][20][22], yet the literature asks many questions at once and often measures intermediate markers. A recent synthesis finds limited efficacy and sparse tissue data [18]. Semaglutide has traveled furthest through the chain, from mechanism to large trials measuring body weight and major cardiovascular or kidney events [9][10][11]. Even there, evidence remains endpoint- and population-specific. Mature evidence means more links in the chain have been tested, not that uncertainty disappears.
How to read an endpoint
An endpoint is the exact result investigators chose to measure. In KPV studies, endpoints include inflammatory signaling, cytokines, experimental disease severity, and tissue repair [1][3][6]. In CJC-1295 studies, the principal endpoints are hormone levels, pulse patterns, and serum protein changes [15][16][17]. In NAD+ precursor work, endpoints range from blood NAD+ to muscle insulin sensitivity and walking distance [19][20][22]. Semaglutide trials include body-weight change and prespecified cardiovascular or kidney composites [9][10][11].
The endpoint determines the permissible sentence. Lower inflammatory signaling supports “modulated an inflammatory pathway,” not “treated human inflammatory disease.” Higher IGF-1 supports “activated the axis,” not “improved recovery.” Higher blood NAD+ supports “raised the measured pool,” not “slowed aging.” Fewer major clinical events in a defined randomized population supports a clinical outcomes claim for that population.
Safety and status are part of the comparison
Semaglutide is an approved prescription medicine with a developed safety literature; gastrointestinal intolerance and biliary disease are established parts of its record, while some low-incidence signals remain unresolved [12]. KPV and CJC-1295 are not approved human medicines. KPV lacks human clinical safety data, while CJC-1295 has only limited early human studies. Unknown does not mean harmless, and it does not mean proven dangerous; it means the uncertainty must be stated.
NAD+ has a different regulatory and quality landscape because oral supplements, precursors, and compounded intravenous products are not interchangeable. Short precursor trials provide some tolerability data [19][22], but they cannot settle every formulation or long-term population. Across all four records, product identity and study equivalence matter. A published result for a defined molecule and preparation does not validate material of uncertain composition.
The useful conclusion
The comparison does not produce a winner. It produces a calibrated map. KPV has an interesting preclinical anti-inflammatory program. Semaglutide has a mature clinical outcomes record with known limitations. CJC-1295 has demonstrated human endocrine activity without established broad benefit. NAD+ has foundational biology and measurable precursor effects, while human clinical meaning remains unsettled.
That is the purpose of the Right Peptides frame: preserve the distance between mechanism, marker, and outcome. The individual pages provide the detail; the reference desk provides the source trail.